Pre-clinical non-viral vectors exploited for <i>in vivo</i> CRISPR/Cas9 gene editing: an overview-Reference-Cited by-同舟云学术

Pre-clinical non-viral vectors exploited for in vivo CRISPR/Cas9 gene editing: an overview

Published:2022 Issue:13 Volume:10 Page:3410-3432
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Rouatbi Nadia¹,McGlynn Tasneem¹,Al-Jamal Khuloud T.¹^ORCID

Affiliation:

1. Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, UK

Abstract

Non-viral delivery technologies for efficient in vivo Clustered Regulatory Interspaced Short Palindromic Repeats (CRISPR/Cas9) gene editing.

Funder

Brain Tumour Charity

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

Link

http://pubs.rsc.org/en/content/articlepdf/2022/BM/D1BM01452H

Reference151 articles.

1. The current landscape of nucleic acid therapeutics

2. Mipomersen Sodium: First Global Approval

3. U.Patel , M.Boucher , L.de Léséleuc and S.Visintini , in Voretigene Neparvovec: An Emerging Gene Therapy for the Treatment of Inherited Blindness , Canadian Agency for Drugs and Technologies in Health , Ottawa (ON) , 2016

4. Small interfering RNA from the lab discovery to patients' recovery

5. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nordihydroguaiaretic Acid-Cross-Linked Phenylboronic Acid-Functionalized Polyplex Micelles for Anti-angiogenic Gene Therapy of Orthotopic and Metastatic Tumors;ACS Applied Materials & Interfaces;2024-06-27

2. AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B;Thrombosis Research;2024-06

3. Non-viral vector-based genome editing for cancer immunotherapy;Biomaterials Science;2024

4. CRISPR-Cas9-based non-viral gene editing therapy for topical treatment of recessive dystrophic epidermolysis bullosa;Molecular Therapy - Methods & Clinical Development;2023-12

5. Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy;Frontiers in Chemistry;2023-09-28